Odd Erik Johansen

Boehringer Ingelheim (Norway)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial”.

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Diabetes Care(2020)10.2337/dc20-0279

N/A

1.9DataRank · unranked

61 citations

Robert D. Toto, Mark E. Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire +12 more

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine(2015)10.1056/nejmoa1504720

N/A

1.4DataRank · unranked

11839 citations

Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel +7 more

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

Clinical Kidney Journal(2020)10.1093/ckj/sfaa225

N/A

0DataRank · unranked

18 citations

Mark E. Cooper, Odd Erik Johansen, Robert D. Toto, Julio Rosenstock, Darren K. McGuire +12 more